stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
— | 353.05 | 239.25 | 274.95 |
+8 more quarters Free account |
Receivables |
121.79 | 110.76 | 109.27 | 106.82 | |
Inventory |
13.74 | 6.06 | 5.99 | 5.40 | |
Total current assets |
531.15 | 484.68 | 373.63 | 404.35 | |
Property, Plant, Equpment (Net) |
1.66 | 9.06 | 9.37 | 8.78 | |
Long-Term Investments |
— | — | 20.57 | 61.16 | |
Long-term assets (Other) |
— | 19.56 | 19.70 | 5.67 | |
Total non-current assets |
59.92 | 73.17 | 91.43 | 109.81 | |
Total Assets |
591.07 | 557.85 | 465.05 | 514.16 | |
Accounts Payable |
14.58 | 11.46 | 10.96 | 15.83 | |
Accrued Expenses |
110.69 | 121.90 | 119.40 | 126.41 | |
Current Part of Debt |
— | 60.17 | 56.53 | 52.20 | |
Current Part of Capital Lease |
1.02 | 1.09 | 1.24 | 1.31 | |
Current Revenue (Deferred) |
10.54 | 12.32 | 5.41 | — | |
Total current liabilities |
195.83 | 208.85 | 195.39 | 196.07 | |
Long Term Debt (Total) |
— | 779.23 | 803.55 | 428.67 | |
Non-current Revenue (Deferred) |
11.61 | 13.46 | 8.83 | — | |
Total non-current liabilities |
792.62 | 803.29 | 823.50 | 437.25 | |
Total liabilities |
988.45 | 1,012.14 | 1,018.90 | 633.31 | |
Additional Paid In Capital |
1,712.34 | 1,693.28 | 1,671.98 | 1,384.86 | |
Common Stock (Net) |
2.56 | 2.55 | 2.54 | 2.13 | |
Retained Earnings |
(2,111.68) | (2,149.60) | (2,227.99) | (1,506.18) | |
Common Equity (Total) |
(397.38) | (454.29) | (553.84) | (119.15) | |
Shareholders Equity (Total) |
(397.38) | (454.29) | (553.84) | (119.15) | |
Shareholders Equity and Liabilities (Total) |
591.07 | 557.85 | 465.05 | 514.16 | |
Shares (Common) |
256.12 | 255.27 | 254.01 | 213.06 | |
Shareholders Equity (Tangible) |
(397.38) | (454.29) | (553.84) | (119.15) | |
Net Debt |
— | 486.35 | 620.83 | 205.92 | |
Total Debt |
— | 839.40 | 860.08 | 480.87 |